Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  letrozole
Find trials that include:  Any drugs shown
Results 1-25 of 31 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70, Postmenopausal
Trial IDs: A5481027, NCI-2015-01375, JS14185, NCT02297438
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Postmenopausal Women With HR+ HER2- aBC
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011A2404, NCI-2016-01811, NCT02941926
Dovitinib Lactate in Combination With Anastrozole, Exemestane, or Letrozole in Treating Patients With Hormone-Receptor Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-535, NCI-2013-00749, NCT01484041
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, NCT01872260
Pazopanib Hydrochloride and Anastrozole or Letrozole in Treating Patients With Advanced Hormone-Resistant Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117513, NCI-2012-00494, NCT01466972
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GO28888, NCI-2014-02653, 2013-000568-28, NCT02273973
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-11, NCI-2015-00998, WI180455, NCT02296801
Ribociclib and Letrozole in Treating Patients with Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1561, NCI-2015-02181, NCT02657928
Letrozole with or without Ribociclib before Surgery in Treating Women with Stage II-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011XUS10T, NCI-2016-00423, STUDY00002972, NCT02712723
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients with Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15295, NCI-2015-02194, NCT02648477
Tamoxifen Citrate or Letrozole with or without Palbociclib in Treating Patients with Stage I-III Invasive Breast Cancer before Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-052, NCI-2016-00893, NCT02764541
Palbociclib, Letrozole, and Trastuzumab Before Surgery in Treating Patients with Estrogen Receptor Positive and HER2 Positive Stage II-III Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201610019, NCI-2016-01516, NCT02907918
A Study of LY3023414 in Participants With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13517, NCI-2016-01472, I6A-MC-CBBA, NCT01655225
Alpelisib and Letrozole with or without Trastuzumab in Post-menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BRE 12101, NCI-2013-00102, CBYL719XUS03T, SU2C B07, NCT01791478
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15252, NCI-2014-01032, I3Y-MC-JPBH, NCT02057133
Everolimus, Letrozole, and Trastuzumab in Treating Patients with Hormone Receptor-Positive and HER2-Positive Advanced Metastatic Breast Cancer or Other Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0119, NCI-2014-01615, NCT02152943
Start Over